Medical Hypotheses
Volume 59, Issue 3 , Pages 239-246 , September 2002

Is lead exposure the principal cause of essential hypertension?

  • H.C Gonick

      Affiliations

    • The Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA
    • The University of California, Los Angeles, California, USA
    • Corresponding Author InformationCorrespondence to: Harvey C. Gonick MD, Nephrology Division, 995 West Tower, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA. Phone: 310-423-7880; Fax: 310-423-3061
    • ,
  • J.R Behari

      Affiliations

    • The Burns and Allen Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA
    • Industrial Toxicology Research Centre, Lucknow, India

Received 30 August 2001 ,Accepted 19 December 2001.

References 

  1. Pirkle JL, Schwartz J, Landis JR, Harlan WR. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am. J. Epidemiol. 1985;121:246–258
  2. Kirkby H, Guntelberg F. Blood pressure and other cardiovascular risk factors of long-term exposure to lead. Scand J. Work Environ. Health. 1985;11:15–19
  3. Osterloh JD, Selby JY, Bernard BP, Becker CE, Menke DJ, Tepper E, et al. Body burdens of lead in hypertensive nephropathy. Arch. Environ. Health. 1989;44:304–310
  4. Micciolo R, Canal L, Maraneli G, Apostoli P. Non-occupational lead exposure and hypertension in northern Italy. Int. J. Epidemiol. 1994;23:312–320
  5. Menditto A, Morisi G, Spagnolo A, Menotti A. Association of blood lead to blood pressure in men aged 55–75 years: effect of selected social and biochemical confounders. NFR Study Group Environ. Health Perspect. 1994;102:107–111
  6. Sanchez-Fructuoso AI, Torralbo A, Arroyo M, Ruilope LM, Santos JL, Cruceyra A, et al. Occult lead intoxication as a cause of hypertension and renal failure. Nephrol. Dial Transplant. 1996;11:1775–1780
  7. Staessen JA, Lauwerys RR, Bulpitt CJ, Fagard R, Lijnen P, Roels H, et al. Is a positive correlation between lead exposure and blood pressure supported by animal experiments?. Curr. Opin. Nephrol. Hypertens. 1994;3:257–263
  8. Staessen J. Low level lead exposure, renal function and blood pressure. Verh. K. Acad. Geneskd. Belg. 1995;57:527–574
  9. Staessen JA, Roels H, Lauwerys RR, Amery A. Low level lead exposure and blood pressure. J. Hum. Hypertens. 1995;9:303–328
  10. Staessen JA, Roels H, Fagard R. Lead exposure and conventional and ambulatory blood pressure: a prospective population study. PheeCad Investigators. JAMA. 1996;275:1563–1570
  11. Korrick SA, Hunter DJ, Rotnitzky A, Hu H, Speizer FE. Lead and hypertension in a sample of middle aged women. Am. J. Public Health. 1999;89:330–335
  12. Wu TN, Shen CY, Ko KN, Guu CF, Gau HJ, Lai JS, et al. Occupational lead exposure and blood pressure. Int. J. Epidemiol. 1996;25:791–796
  13. Victery W, Vander AJ, Shulak JM, Schoeps P, Julius S. Lead, hypertension, and the renin angiotensin system in rats. J. Lab. Clin. Med. 1982;99:354–362
  14. Chai SS, Webb RC. Effects of lead on vascular reactivity. Environ. Health Perspect. 1988;78:85–89
  15. Gonick HC, Ding Y, Bondy SC, Ni Z, Vaziri ND. Lead-induced hypertension. I. Interplay of nitric oxide and reactive oxygen species. Hypertension. 1997;30:1487–1492
  16. Sharp DS, Becker CE, Smith AH. Chronic low level lead exposure: its role in pathogenesis of hypertension. Med. Toxicol. 1987;2:210–232
  17. Khalil-Manesh F, Gonick HC, Weiler EWJ, Prins BA, Weber MA, Purdy RE. Lead-induced hypertension: possible role of endothelial factors. Am. J. Hypertens. 1993;6:723–729
  18. Khalil-Manesh F, Gonick HC, Weiler EWJ, Prins B, Weber MA, Purdy R, et al. Effect of chelation treatment with dimercaptosuccinic acid (DMSA) on lead-related blood pressure changes. Environ. Res. 1994;65:86–99
  19. Wu TN, Shen CY, Ko KN, Guu CF, Gau HJ, Lai JS, et al. Occupational lead exposure and blood pressure. Int. J. Epidemiol. 1996;25:791–796
  20. Pirkle JL, Kaufmann RB, Brody DJ, Hickman T, Gunter FW, Paschal DC. Exposure of the U.S. population to lead, 1991–1994. Environ. Health Perspect. 1998;106(11):745–750
  21. Alessio L. Relationship between `chelatable lead' and the indicator of exposure and effect in current and past occupational exposure. Sci. Total Environ. 1988;71(3):293–299
  22. Gerhardsson L, Borjesson J, Mattson S, Schutz A, Skerfving S. Chelated lead in relation to lead in bone and ALAD genotype. Environ. Res. 1999;80:389–398
  23. Batuman V, Landy E, Maseka JK, Wedeen RP. Contribution of lead to hypertension with renal impairment. New Engl. J. Med. 1983;7:17–21
  24. Lin JL, Lim PS. Does lead play a role in the development of renal insufficiency in some patients with essential hypertension?. J. Hum. Hypertens. 1994;8:495–500
  25. Hu H, Pepper L, Goldman R. Effect of repeated occupational exposure to lead, cessation of exposure, and chelation on levels of lead in bone. Am. J. Ind. Med. 1991;20(6):723–735
  26. Rabinowitz MB, Wetherill GW, Kopple JD. Kinetic analysis of lead metabolism in healthy humans. J. Clin. Invest. 1976;58:260–270
  27. Nilsson V, Attewal R, Christoffersson J-O, Schutz A, Ahlgren L, Skerfving S, et al. Kinetics of lead in bone and blood after the end of occupational exposure. Pharmacol. Toxicol. 1991;68:477–484
  28. Hu H, Payto M, Korrick S, Aro A, Sparrow D, Weiss ST, et al. Determinants of bone and blood lead levels among community-exposed middle-aged to elderly women. The normative aging study. Am. J. Epidemiol. 1996;144:749–759
  29. Emmerson BT. Chronic lead nephropathy. The diagnostic use of calcium EDTA and the association with gout. Australas. Ann. Med. 1963;12:310–324
  30. Emmerson BT. The clinical differentiation of lead gout from primary gout. Arthritis Rheum. 1968;11(5):623–634
  31. Franklin SS. Aging and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. J. Hypertens. 1999;17(suppl. 5):S29–S36
  32. Wolf S, Wolf TD. A preliminary study in medical anthropology in Brunei, Borneo. Pavlov J. Biol. Sci. 1978;13:42–54
  33. Katsivo MN, Apeagyie F. Hypertension in Kitui district: a comparative study between urban and rural populations. East Afr. Med. J. 1991;68:531–538
  34. Lore W. Epidemiology of cardiovascular diseases in Africa with special reference to Kenya: an overview. East Afr. Med. J. 1993;70:357–361
  35. Mancilha Carvalho JJ, Baruzzi RG, Howard PF, Poulter N, Alpers MP, Franco LJ, et al. Blood pressure in four remote populations in the INTERSALT study. Hypertension. 1989;14(3):238–246
  36. Hollenberg NK, Martinez G, McCullough M, Meinking T, Passan D, Preston M, et al. Aging, acculturation, salt intake, and hypertension in the Kuna of Panama. Hypertension. 1997;29(1, Pt. 2):171–176
  37. He J, Klag MJ, Whelton PK, Chen J-Y, Mo J-P, Qian M-C, et al. Migration, blood pressure pattern, and hypertension: the Yi migrant study. Am. J. Epidemiol. 1991;134(10):1085–1101
  38. Beilin LJ, Puddey IB, Burke V. Lifestyle and hypertension. Am. J. Hypertens. 1999;12(9, Pt. 1):934–945
  39. Hecker LH, Allen HE, Bertram D, Dinman D. Heavy metal levels in acculturated and unacculturated populations. Arch. Environ. Health. 1974;29:181–218
  40. Piomelli S, Corash L, Corash MB, Seaman C, Mushak P, Glover B, et al. Blood lead concentrations in remote Himalayan population. Science. 1980;5:1135–1137
  41. Chrysant GS, Bakir S, Oparil S. Dietary salt reduction in hypertension–what is the evidence and why is it still controversial?. Prog. Cardiovasc. Dis. 1999;42(1):23–38
  42. Whelton PK, He J. Potassium in preventing and treating high blood pressure. Sem. Nephrol. 1999;19(5):494–499
  43. Lascaux-Lefebvre V, Ruidavets J, Arveiler D, Amouyel P, Haas B, Cottel D, et al. Influence of parental history of hypertension on blood pressure. J. Hum. Hypertens. 1999;13(9):631–636
  44. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension. 1986;8(suppl. II):II-127–II-134
  45. Chrysant GS, Bakir S, Oparil S. Dietary salt reduction in hypertension – what is the evidence and why is it still controversial?. Prog. Cardiovasc. Dis. 1999;31(1):23–38
  46. Campese VM, Bianchi S, Bigazzi R. Hypertension, hyperlipidemia and microalbuminuria. Contrib. Nephrol. 1997;120:11–21
  47. Ferri C, Bellini C, Desideri G, Valenti M, DeMattia G, Santucci A, et al. Relationship between insulin resistance and nonmodulating hypertension: linkage of metabolic abnormalities and cardiovascular risk. Diabetes. 1999;48(8):1623–1630
  48. Raij L. Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension. Semin. Nephrol. 1999;19(3):296–303
  49. deWardener HE. Kidney, salt intake, and Na+–K+-ATPase inhibitors in hypertension: 1990 Corcoran Lecture. Hypertension. 1991;17:830–836
  50. Gonick HC, Kramer HJ, Paul W, Lu E. Circulating inhibitor of sodium-potassium-activated adenosine triphosphatase after expansion of extracellular fluid volume in rats. Clin. Sci. Mol. Med. 1977;53:329–334
  51. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and an hypothesis. Am. J. Physiol. 1977;232:165–173
  52. Iwaoka T, Umeda T, Miura F, Inoue J, Sasaki M, Naomi S, et al. Renal sodium handling and sodium transport inhibitor in salt-sensitive essential hypertension. J. Hypertens. 1991;9(1):49–54
  53. Gonick HC, Weiler EWJ, Khalil-Manesh F, Weber MA. Predominance of high molecular weight Na–K-ATPase inhibitor in essential hypertension. Am. J. Hypertens. 1993;6:680–687
  54. Kramer HJ, Gonick HC, Lu E. In vitro inhibition of Na–K-ATPase by trace metals: relation to renal and cardiovascular damage. Nephron. 1986;44:329–336
  55. Weiler E, Khalil-Manesh F, Gonick HC. Effects of lead and a low molecular weight endogenous plasma inhibitor on the kinetics of sodium–potassium-activated adenosine triphosphatase and potassium activated p-nitrophenyl-phosphatase. Clin. Sci. 1990;79:185–192
  56. Piccinini F, Favalli L, Chiari MC. Experimental investigations on the contraction induced by lead in arterial smooth muscle. Toxicology. 1977;8:43–51
  57. Batuman V, Dreisbach A, Chun E, Naumoff M. Lead increases red cell sodium–lithium countertransport. Am. J. Kidney Dis. 1989;14:200–203
  58. Canessa M, Adragna N, Solomon HS, Connolly TM, Tosteson DC. Increased sodium–lithium countertransport in red cells of patients with essential hypertension. N. Engl. J. Med. 1980;302:772–776
  59. Kaplan NM, Kern DC, Holland OB, Kramer NJ, Higgins J, Gomez-Sanchez C. The intravenous furosemide test: a simple way to evaluate renin responsiveness. Ann. Int. Med. 1976;84(6):639–645
  60. Fleischer N, Mouw R, Vander AJ. Chronic effects of lead on renin and renal sodium excretion. J. Lab. Clin. Med. 1980;95:759–770
  61. Boscolo P, Carmignani M. Neurohumoral blood pressure regulation in lead exposure. Environ. Health Perspect. 1988;78:101–106
  62. Vander AJ. Chronic effects of lead on renin–angiotensin system. Environ. Health Perspect. 1988;78:77–83
  63. Chang HR, Chen SS, Tsao DA, Cheng JT, Ho CK, Yu HS. Reduced vascular beta-adrenergic receptors and catecholamine response in rats with lead-induced hypertension. Arch. Toxicol. 1997;71:778–781
  64. Morgan JM. Hyperkalemia and acidosis in lead nephropathy. South. Med. J. 1976;69(7):881–883 886
  65. Huang BS, Leenen FH. Both brain angiotensin II and `ouabain' contribute to sympathoexcitation and hypertension in Dahl S rats on high salt intake. Hypertension. 1998;32(6):1028–1033
  66. Miyajima E, Yamada Y. Reduced sympathetic inhibition in salt-sensitive Japanese young adults. Am. J. Hypertens. 1999;12(2, Pt. 102):1195–1200
  67. Jacobs MC, Lenders JW, Willemsen JJ, Thien T. Adrenomedullary secretion of epinephrine is increased in mild essential hypertension. Hypertension. 1997;29(6):1303–1308
  68. Bono M, Cases A, Calls J, Gaya J, Jimenez W, Carretero J, et al. Effect of antihypertensive treatment on the increased beta 2-adrenoreceptor density in patients with essential hypertension. Am. J. Hypertens. 1995;8:487–493
  69. Damase-Michel C, Bompart G, Durrieu G, Montastruc P, Girolami JP. Relationship between kallikrein secretion, kallikrein excretion and beta-adrenoreceptors in kidney cortical slices from neurogenic hypertensive dogs. Br. J. Pharmacol. 1995;116:1704–1710
  70. deCastro FJ. Plasma catecholamine activity in chronic lead poisoning. Vet. Hum. Toxicol. 1990;32:152–153
  71. Uehara Y, Ishii M, Ikeda T, Atarashi K, Takeda T, Murao S. Plasma levels of 6-keto-prostaglandin F1 alpha in normotensive subjects and patients with essential hypertension. Prostaglandins Leukot. Med. 1983;11(1):95–104
  72. Ritter JM, Brett SE, Woods JD, Benjamin N, Stratton PD, Barrow SE. Prostacyclin biosynthesis in essential hypertension before and during treatment. J. Hum. Hypertens. 1996;19:37–42
  73. Cardenas A, Roels H, Bernard AM, Barbon R, Buchet JP, Lauwery RR, et al  Markers of early renal changes induced by industrial pollutants. II. Application to workers exposed to lead. Br. J. Ind. Med. 1993;50:28–36
  74. Hotter G, Fels LM, Closa D, Rosello J, et al.  Altered levels of urinary prostanoids in lead exposed workers. Topx. Lett. 1995;77:309–312
  75. Gonick HC, Ding Y, Vaziri ND. Effect of low lead exposure on eicosanoid excretion in rats. Prostaglandins Other Lipid Mediators. 1998;55(2):77–82
  76. Ferro CJ, Webb DJ. Endothelial dysfunction and hypertension. Drugs. 1997;53(suppl. 1):30–41
  77. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 1993;91:2546–2551
  78. Miller FJ, Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ. Res. 1998;82:1298–1305
  79. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320:454–456
  80. Beckman JS, Crow JP. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem. Soc. Trans. 1993;21:330–334
  81. Beckman JS, Ye YZ, Anderson P, Chen J, Accavetti MA, Tarpey MM, et al. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol. Chem. Hoppe Seyler. 1994;375:81–88
  82. Millgard J, Lind L. Acute hypertension impairs endothelium-dependent vasodilation. Clin. Sci. 1998;95:601–607
  83. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension. 1997;30:405–408
  84. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am. J. Hypertens. 1991;4:303–308
  85. Schiffrin EL. Endothelin and endothelin antagonists in hypertension. J. Hypertens. 1998;16:1891–1895
  86. Schiffren EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J. Hypertens. 1997;15:57–63
  87. Ding Y, Vaziri ND, Gonick HC. Lead-Induced hypertension. II. Response to sequential infusions of l-arginine, superoxide dismutase and nitroprusside. Environ. Res. 1998;6(2):107–113
  88. Vaziri ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int. 1997;52:1042–1046
  89. Ding Y, Vaziri ND, Gonick HC. Lead-induced hypertension III. Increased hydroxyl radical production. Am. J. Hypertens. 2001;14:169–173
  90. Ding Y, Gonick HC, Vaziri ND. Lead promotes hydroxyl radical generation and lipid peroxidation in cultured aortic endothelial cells. Am. J. Hypertension. 2000;13(5, Pt. 1):552–555
  91. Koska J, Syrova D, Blazicek P, Marko M, Grua JD, Kvetnansky R, et al. Malondialdehyde, lipofuscin and activity of antioxidant enzymes during physical exercise in patients with essential hypertension. J. Hypertens. 1999;17(4):529–535
  92. Digiesi V, Oliviero C, Gianno V, Rossetti M, Fiorillo C, Oradei A, et al. Reactive metabolites of oxygen, lipid peroxidation, total antioxidant capacity and vitamin E in essential arterial hypertension. Clin. Ter. 1997;148(11):515–519
  93. Lacy F, O'Connor DT, Schmid-Schonbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J. Hypertens. 1998;16(3):291–303
  94. Kumar KV, Das UN. Are free radicals involved in the pathobiology of human essential hypertension?. Free Radio Res. Commun. 1993;19(1):59–66
  95. Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int. 1998;53(6):1748–1754
  96. Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F. Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif. 1999;17(2–3):99–106
  97. Dekker GA. Etiology and pathophysiology of preeclampsia. Zentralbl. Gynakol. 1994;116(2):57–60
  98. Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress?. Metabolism. 1995;44(3):363–368
  99. Swei A, Lacy F, Delano FA, Parks DA, Schmid-Schonbein GW. A mechanism of oxygen free radical production in the Dahl hypertensive rat. Microcirculation. 1999;6(3):179–187
  100. White BH, Sidhu A. Increased oxidative stress in renal proximal tubules of the spontaneously hypertensive rat: a mechanism for defective dopamine DIA receptor/G-protein coupling. J. Hypertens. 1998;16(11):1659–1665
  101. Gupta R, Sharma AK. Prevalence of hypertension and subtypes in an Indian rural population: clinical and electrocardiographic correlates. J. Hum. Hypertens. 1994;8(11):823–829
  102. Gupta R, Guptha S, Gupta VP, Prakash H. Prevalence and determinants of hypertension in the urban population of Jaipur in western India. J. Hypertens. 1995;3(10):1193–1200

PII: S0306-9877(02)00207-4

Medical Hypotheses
Volume 59, Issue 3 , Pages 239-246 , September 2002

Article Tools

* Image Usage & Resolution